60115-45-9

Basic information

• Product Name: S-2-NITROPHENYL-L-CYSTEINE
• Synonyms: S-2-NITROPHENYL-L-CYSTEINE;H-CYS(SONP)-OH;S-o-nitrophenyl-L-cysteine;L-Cysteine,S-(2-nitrophenyl)-
• CAS NO: 60115-45-9
• Molecular Formula: C₉H₁₀N₂O₄S
• Molecular Weight: 242.25
• Mol File: 60115-45-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 431.3°C at 760 mmHg
• Flash Point: 214.6°C
• Appearance: /
• Density: 1.47g/cm³
• Vapor Pressure: 3.32E-08mmHg at 25°C
• Refractive Index: 1.65
• CAS DataBase Reference: S-2-NITROPHENYL-L-CYSTEINE(CAS DataBase Reference)
• NIST Chemistry Reference: S-2-NITROPHENYL-L-CYSTEINE(60115-45-9)
• EPA Substance Registry System: S-2-NITROPHENYL-L-CYSTEINE(60115-45-9)

Safety Data

• Hazardous Substances Data: 60115-45-9(Hazardous Substances Data)

Usage

General Description

S-2-NITROPHENYL-L-CYSTEINE is a chemical compound that is derived from the amino acid L-cysteine and contains a nitrophenyl group. It is often used in the study of protein interactions and enzyme kinetics, as well as in the synthesis of various chemical compounds. S-2-NITROPHENYL-L-CYSTEINE is known for its ability to undergo reversible reactions with proteins and other biomolecules, making it a valuable tool in biochemical research. It has also shown potential for use in drug development and disease treatment due to its ability to target specific biological pathways. Overall, S-2-NITROPHENYL-L-CYSTEINE is a versatile and important chemical compound with various applications in the fields of biochemistry, pharmaceuticals, and biotechnology.

InChI:InChI=1/C9H10N2O4S/c10-6(9(12)13)5-16-8-4-2-1-3-7(8)11(14)15/h1-4,6H,5,10H2,(H,12,13)/t6-/m0/s1

Upstream product

• 91088-54-9 N-acetyl-S-(2-nitro-phenyl)-L-cysteine 
• 52-90-4 L-Cysteine 
• 88-74-4 2-nitro-aniline 
• 1493-27-2 ortho-nitrofluorobenzene 
• 528-29-0 1,2-Dinitrobenzene 
• 56-89-3 L-cystine 
• 49732-37-8 2-Nitrobenzenediazonium Bisulfate 
• 88-73-3 2-Chloronitrobenzene 
• 7669-54-7 2-nitrobenzenesulfenyl chloride 

Downstream Products

• 356548-98-6 (2R)-2-[(tert-butoxycarbonyl)amino]-3-[(2-nitrophenyl)sulfanyl]propanoic acid 
• 95779-48-9 tert-butyl 3(R)-[1(S)-ethoxycarbonyl-3-phenylpropyl]amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-5-acetate 
• 95779-47-8 tert-butyl 3(R)-[1(R)-ethoxycarbonyl-3-phenylpropyl]amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-5-acetate 
• 95779-49-0 tert-butyl 3(R)-[1(S)-ethoxycarbonyl-3-cyclohexylpropyl]amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-5-acetate 
• 95779-50-3 (R)-2-((R)-5-tert-Butoxycarbonylmethyl-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-ylamino)-4-cyclohexyl-butyric acid ethyl ester 
• 103604-00-8 tert-butyl (R)-3-<(S)-1-ethoxycarbonyl-3-cyclohexylpropyl>amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-5-α-methylacetate 
• 103604-00-8 tert-butyl (R)-3-<(R)-1-ethoxycarbonyl-3-cyclohexylpropyl>amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-5-α-methylacetate 
• 103584-46-9 (S)-2-[(R)-5-(1-Carboxy-ethyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-ylamino]-4-cyclohexyl-butyric acid ethyl ester; hydrochloride 
• 103584-46-9 (R)-2-[(R)-5-(1-Carboxy-ethyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-ylamino]-4-cyclohexyl-butyric acid ethyl ester; hydrochloride 
• 95779-55-8 3(R)-[1(S)-ethoxycarbonyl-3-cyclohexylpropyl]amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-5-acetic acid hydrochloride 
• 95779-56-9 (R)-2-((R)-5-Carboxymethyl-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-ylamino)-4-cyclohexyl-butyric acid ethyl ester; hydrochloride 
• 95779-61-6 C₂₁H₂₀N₂O₅S^(2-)*2Na⁽¹⁺⁾ 
• 98413-85-5 2-((R)-5-Carboxymethyl-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-ylamino)-4,4-diphenyl-butyric acid ethyl ester; hydrochloride 
• 98413-71-9 3(R)-[1(S)-benzyloxycarbonyl-3-phenylpropyl]amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-5-acetic acid hydrochloride 

Relevant articles and documents

Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor α release in vitro and in vivo

To search for TNF-α (tumor necrosis factor α) converting enzyme (TACE) inhibitors, we designed a new class of macrocyclic hydroxamic acids by linking the P1 and P2′ residues of acyclic anti-succinate-based hydroxamic acids. A variety of residues including amide, carbamate, alkyl, sulfonamido, Boc-amino, and amino were found to be suitable P1 P1-P2′ linkers. With an N-methylamide at P3′, the 13-16-membered macrocycles prepared exhibited low micromolar activities in the inhibition of TNF-α release from LPS-stimulated human whole blood. Further elaboration in the P3′-P4′ area using the cyclophane and cyclic carbamate templates led to the identification of a number of potent analogues with IC50 values of ≤0.2 μM in whole blood assay (WBA). Although the P3′ area can accommodate a broad array of structurally diversified functional groups including polar residues, hydrophobic residues, and amino and carboxylic acid moieties, in both the cyclophane series and the cyclic carbamate series, a glycine residue at P3′ was identified as a critical structural component to achieve both good in vitro potency and good oral activity. With a glycine residue at P3′, an N-methylamide at P4′ provided the best cyclophane analogue, SL422 (WBA IC50 = 0.22 μM, LPS-mouse ED50 = 15 mg/kg, po), whereas a morpholinylamide at P4′ afforded the most potent and most orally active cyclic carbamate analogue, SP057 (WBAIC50 = 0.067 μM, LPS-mouse ED50 = 2.3 mg/kg, po). Further profiling for SL422 and SP057 showed that these macrocyclic compounds are potent TACE inhibitors, with Ki values of 12 and 4.2 nM in the porcine TACE assay, and are broad-spectrum MMP inhibitors. Pharmacokinetic studies in beagle dogs revealed that SL422 and SP057 are orally bioavailable, with oral bioavailabilities of 11% and 23%, respectively.

S-aryl-L-cysteine S,S-dioxides: Design, synthesis, and evaluation of a new class of inhibitors of kynureninase

-

Synthesis and angiotensin converting enzyme inhibitory activity of 1,5-benzothiazepine and 1,5-benzoxazepine derivatives. I

-